Back to EZorb Newsletter Index




In this issue:


1. Share Success: Letters From Readers
2. Research News: Breast Cancer Risk Not Different for IVF-Treated Women
3. Useful Links
4. Calcium Absorption Test
5. What Are Others Saying About EZorb and Marvlix?

1. Share Success: Letters From Readers 


Letter I: From Linda H.

Received at Customer Service Voice Mail Friday, Apr 22 2016



Hi my name is Linda H. I've been taking your product EZorb for a while. I just want you to know I had a bone density scan.

My last one was 4 years ago, and the doctor just called and said there's no change for 4 years. So your product really works, that EZorb.

Thanks Guys. Again this is Lind H. from Carol Stream IL. Bye.

Letter II: From Anonymous

Received at Testimonial Submit Form Thursday, April 28, 2016 at 20:59:34



My rheumatologist was outraged when he found out that I was not taking the prescription Fosamax. He ordered another Bone Density Test, and when I went back for a follow-up visit, he told me to keep taking what I'd been taking- that was my EZorb!

I'm so glad I took the risk of losing my doctor because the EZorb improved my bone density even though I am on daily prednisone!

Letter III: From Marmee

Received at Testimonial Submit Form Monday, December 28, 2015 at 19:11:53



Hi, my name is Marmee. I am 66 and was diagnosed with osteopenia about 4 months ago. My doctor prescribed Fosomax which I said I would begin taking and then thought better about. Never filled the prescription.

I had taken EZorb a few years ago but didn't really get with the program. Ordered EZorb again and took 8 pills a day religiously for 3 months. Now I am on the maintenance amount of 4 pills a day.

I cannot say for absolutely sure that my bones are stronger yet, but I can say that my hands and lower back arthritis have gotten MUCH MUCH better!

Have stopped taking my arthritis pills. Right there the price of EZorb has become easier on my wallet.

Love this product, and am among the ranks who say they will take EZorb FOREVER!

From the Desk of EZorb Newsletter Editor:

This newsletter is now read by over 95,000 subscribers worldwide. Success stories you have contributed over the years have had a great impact on many people's quality of life. Your continuous support will be greatly appreciated by tens of thousands who have been suffering and would continuously suffer, without your help! Please email your story to sharesuccess @ or simply post it at Testimonial Submit Form. Your personal information will never be revealed to the public. If your testimonial is selected for publication, you will receive a free gift of 3 bottles of EZorb Capsules, EZorb Powder, or Marvlix of your choice.

2. Research News: Breast Cancer Risk Not Different for IVF-Treated Women


Women who receive in vitro fertilization (IVF) treatment do not have a higher risk of developing breast cancer in the long term versus those who receive non-IVF therapy and the general population, say Dutch researchers.

They report on 25,108 participants of the OMEGA historical cohort, 19,158 of whom underwent IVF between 1983 and 1995, while 5950 had other fertility treatments (e.g., tubal surgery) between 1980 and 1995 in the Netherlands.

A total of 839 cases of first invasive breast cancer and 109 of ductal carcinoma in situ were recorded over a median follow-up of 21.1 years, according to the study published in JAMA.

Neither IVF-treated women nor those in the non-IVF group had an elevated breast cancer risk relative to the general population, with standardized incidence ratios (SIRs) of 1.01 and 1.00, respectively.

And longer time since IVF or non-IVF treatment (>=20 years) did not affect breast cancer risk either, with respective SIRs of 0.92 and 1.03.

When the two groups that received fertility therapy were compared, the cumulative incidence of breast cancer at 55 years of age was a comparable 3.0% in the IVF group and 2.9% in the non-IVF group. And the risk of breast cancer did not differ significantly between groups, with a hazard ratio of 1.01 after adjusting for age at first birth and parity.

Among IVF-treated participants, receipt of seven or more IVF cycles versus one or two cycles reduced the risk of long-term breast cancer by a significant 45%. A poor response to the first IVF cycle – that is, collection of fewer than four oocytes – also significantly protected against breast cancer, lowering the risk by 23%.

Investigator Flora van Leeuwen, from the Netherlands Cancer Institute in Amsterdam, and co-workers emphasize that "these findings are consistent with absence of a significant increase in long-term risk of breast cancer among IVF-treated women."

But they caution: "Because more recent IVF regimens largely consist of protocols with antagonists and shorter periods of down-regulation (possibly associated with less risk reduction), and improved success rates (associated with fewer cycles), it is uncertain how study results generalize to more contemporary IVF treatment.

"Furthermore, because only 14% of the cohort had reached age 60 years, follow-up is necessary to evaluate postmenopausal breast cancer risk after ovarian stimulation for IVF."

Original research was published in JAMA 2016; 316: 300–312.

3. Useful Links

Frequently Asked Questions & Answers

EZorb Clinical Studies

Marvlix Benefits

Order Now



4. Calcium Absorption Test

EZorb Calcium has set a new world record of absorption rate. You can compare EZorb with other calcium supplements by using the simple step-by-step instructions we provide. E-mail your request to test @ for a copy of the instructions.



5. What Are Others Saying About EZorb and Marvlix?

EZorb and Marvlix have restored confidence in thousands of men and women. It has brought happiness and healthy life to families around the world. Click here to read what people say about EZorb and Marvlix.

Back to EZorb Newsletter Index

  Copyright 2016 Elixir Industry